Chongqing Zhifei Biological Products Co.Ltd(300122) 4 on the evening of April 27, the annual report of 2021 was released. In 2021, the operating revenue reached 30.652 billion yuan, a year-on-year increase of 101.79%; The net profit attributable to shareholders of listed companies was 10.209 billion yuan, a year-on-year increase of 209.23%; The basic earnings per share is 6.38 yuan. The company plans to distribute a cash dividend of 6 yuan (including tax) for every 10 shares to all shareholders.
According to the annual report, in 2021, the company actively responded to various challenges, ensured the R & D progress and production supply of covid-19 vaccine and other products, increased R & D investment, innovated R & D technology, continued to focus on the company’s business and development objectives, and realized the sustainable growth of the company’s main business through the “technology + market” two wheel driven development model.
The company signed a cooperative R & D agreement with the Institute of Microbiology, Chinese Academy of Sciences. The recombinant new coronavirus protein vaccine (CHO cell) (zhikeweide) jointly developed by the company was launched in June, 2020. The company promoted the R & D progress without investment to ensure production and supply. During the reporting period, zhikeweide was put into emergency use in March 2021 to serve the implementation of the national mass immunization plan and build a public health and immune barrier. As of the disclosure date of the report, the company’s recombinant covid-19 vaccine was approved for conditional listing in 2022 and served as a sequential booster to protect more than 100 million people.
The company has a relatively perfect layout in terms of tuberculosis products. On June 16, 2021, the company announced that its own product Mycobacterium vaccae (micro card) for injection was approved to increase indications and prevent pulmonary tuberculosis among people with latent infection of Mycobacterium tuberculosis. The company’s tuberculosis product micro card and recombinant Mycobacterium tuberculosis fusion protein (EC) (Yika) have jointly constructed the “diagnosis prevention treatment” system of pulmonary tuberculosis.
R & D innovation has always been the internal driving force of the company’s development. Since its listing in 2010, the cumulative revenue of the company’s independent products has exceeded 16.8 billion yuan.
On the same day, the company released the report for the first quarter of 2022. In the first quarter, the operating revenue was 8.841 billion yuan, a year-on-year increase of 125.16%; The net profit attributable to shareholders of listed companies was 1.923 billion yuan, a year-on-year increase of 104.95%; The basic earnings per share is 1.2 yuan.
